Myriad Genetics' board of directors has nominated Louise Phanstiel as its new chair. Phanstiel has served as a director at Myriad since September 2009, has chaired the audit committee and been a member of the nominating and governance committee. She has held various positions at insurer Anthem, and was a partner at PricewaterhouseCoopers. Phanstiel has previously served on the boards of Verastem and Inveresk Research Group.
John Henderson, meanwhile, has resigned as chair of Myriad's board, but will continue to serve as a director. "This change in the leadership of the board is a reflection of the changing environment in which Myriad Genetics operates," Henderson said in a statement. "While the company remains focused on providing critical health care information for the patient, there also is a need to ensure optimization of the processes, which ensure efficient delivery of results, while managing business operations effectively."